Search Results - "HAVRDOVA, E"

'Hidden' factors influencing quality of life in patients with multiple sclerosis by Lysandropoulos, A. P., Havrdova, E.

“…Traditional outcome measures for patients with multiple sclerosis (MS), whether in clinical trials or clinical practice, are currently in question. The…”
Get full text

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

On-line pilates program as an alternative to conventional rehabilitation therapy for people with multiple sclerosis, pilot study by Vetrovska, R., Prochazkova, R., Kubala Havrdova, E., Novotna, K.

“…Restrictions in physical activity during Covid-19 pandemic had an impact on exercise activities on people with chronic diseases such as multiple sclerosis, for…”
Get full text

Positive Effect of a Cooling Cap on Functional Performance in Thermosensitive People with Multiple Sclerosis: A Randomized Controlled Trial by Novotna, K., Dedinova, K., Menkyova, I., Uher, T., Kubala Havrdova, E., Angerova, Y.

“…Background. Up to 80% of people with MS experience worsening of their condition upon an increase in body temperature. Therefore, various options of cooling are…”
Get full text

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis by Vollmer, T. L., Sorensen, P. S., Selmaj, K., Zipp, F., Havrdova, E., Cohen, J. A., Sasson, N., Gilgun-Sherki, Y., Arnold, D. L.

“…The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and descriptively compared laquinimod…”
Get full text

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study by Comi, G, Prof, Pulizzi, A, MD, Rovaris, M, MD, Abramsky, O, Prof, Arbizu, T, MD, Boiko, A, Prof, Gold, R, Prof, Havrdova, E, Prof, Komoly, S, Prof, Selmaj, KW, Prof, Sharrack, B, MD, Filippi, M, MD

“…Summary Background A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well…”
Get full text

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies by Havrdova, E., Giovannoni, G., Gold, R., Fox, R. J., Kappos, L., Phillips, J. Theodore, Okwuokenye, M., Marantz, J. L.

“…Background and purpose Significant effects on clinical/neuroradiological disease activity have been reported in patients with relapsing–remitting multiple…”
Get full text

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study by Kuhle, J, Disanto, G, Dobson, R, Adiutori, R, Bianchi, L, Topping, J, Bestwick, JP, Meier, U-C, Marta, M, Costa, G Dalla, Runia, T, Evdoshenko, E, Lazareva, N, Thouvenot, E, Iaffaldano, P, Direnzo, V, Khademi, M, Piehl, F, Comabella, M, Sombekke, M, Killestein, J, Hegen, H, Rauch, S, D’Alfonso, S, Alvarez-Cermeño, JC, Kleinová, P, Horáková, D, Roesler, R, Lauda, F, Llufriu, S, Avsar, T, Uygunoglu, U, Altintas, A, Saip, S, Menge, T, Rajda, C, Bergamaschi, R, Moll, N, Khalil, M, Marignier, R, Dujmovic, I, Larsson, H, Malmestrom, C, Scarpini, E, Fenoglio, C, Wergeland, S, Laroni, A, Annibali, V, Romano, S, Martínez, AD, Carra, A, Salvetti, M, Uccelli, A, Torkildsen, Ø, Myhr, KM, Galimberti, D, Rejdak, K, Lycke, J, Frederiksen, JL, Drulovic, J, Confavreux, C, Brassat, D, Enzinger, C, Fuchs, S, Bosca, I, Pelletier, J, Picard, C, Colombo, E, Franciotta, D, Derfuss, T, Lindberg, RLP, Yaldizli, Ö, Vécsei, L, Kieseier, BC, Hartung, HP, Villoslada, P, Siva, A, Saiz, A, Tumani, H, Havrdová, E, Villar, LM, Leone, M, Barizzone, N, Deisenhammer, F, Teunissen, C, Montalban, X, Tintoré, M, Olsson, T, Trojano, M, Lehmann, S, Castelnovo, G, Lapin, S, Hintzen, R, Kappos, L, Furlan, R, Martinelli, V, Comi, G, Ramagopalan, SV, Giovannoni, G

“…Background and objective: We explored which clinical and biochemical variables predict conversion from clinically isolated syndrome (CIS) to clinically…”
Get full text

Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis by BERGSLAND, N, HORAKOVA, D, DWYER, M. G, DOLEZAL, O, SEIDL, Z. K, VANECKOVA, M, KRASENSKY, J, HAVRDOVA, E, ZIVADINOV, R

“…Recent studies have shown that selective regional, but not global, GM atrophy occurs from clinical onset to conversion to clinically definite MS. Our aim was…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder by Stastna, D., Vachova, M., Dusek, P., Fistravec, G., Drahota, J., Menkyova, I., Varju, E., Horakova, D., Kubala Havrdova, E., Nytrova, P.

“…•No antiCD20-treated MS/NMOSD patients developed COVID-19 after receiving evusheld.•Three antiCD20-treated patients in the matched control group developed…”
Get full text

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS by Zivadinov, R, Horakova, D, Bergsland, N, Hagemeier, J, Ramasamy, D P, Uher, T, Vaneckova, M, Havrdova, E, Dwyer, M G

“…Disappearance of T2 lesions into CSF spaces is frequently observed in patients with MS. Our aim was to investigate temporal changes of cumulative atrophied…”
Get full text

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study by Comi, G., Abramsky, O, Arbizu, T, Boyko, A, Gold, R, Havrdová, E, Komoly, S, Selmaj, K, Sharrack, B, Filippi, M

“…Background: Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing—remitting MS (RRMS) patients. Objectives:…”
Get full text

Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis by Tyblova, M., Kalincik, T., Zikan, V., Havrdova, E.

“…Background and purpose The prevalence of osteopenia and osteoporosis is higher amongst patients with multiple sclerosis in comparison with the general…”
Get full text

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis by Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T, Leray, E

“…Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two…”
Get full text

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach by Uher, T., Vaneckova, M., Sormani, M. P., Krasensky, J., Sobisek, L., Dusankova, J. Blahova, Seidl, Z., Havrdova, E., Kalincik, T., Benedict, R. H. B., Horakova, D.

“…Background and purpose While impaired cognitive performance is common in multiple sclerosis (MS), it has been largely underdiagnosed. Here a magnetic resonance…”
Get full text

Survey of diagnostic and treatment practices for multiple sclerosis in Europe by Fernández, O., Delvecchio, M., Edan, G., Fredrikson, S., Gionvannoni, G., Hartung, H.‐P., Havrdova, E., Kappos, L., Pozzilli, C., Soerensen, P. S., Tackenberg, B., Vermersch, P., Comi, G.

“…Background and purpose Up‐to‐date information is needed on the extent to which neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly…”
Get full text

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium by Rup, B., Pallardy, M., Sikkema, D., Albert, T., Allez, M., Broet, P., Carini, C., Creeke, P., Davidson, J., De Vries, N., Finco, D., Fogdell‐Hahn, A., Havrdova, E., Hincelin‐Mery, A., C. Holland, M., H. Jensen, P. E., Jury, E. C., Kirby, H., Kramer, D., Lacroix‐Desmazes, S., Legrand, J., Maggi, E., Maillère, B., Mariette, X., Mauri, C., Mikol, V., Mulleman, D., Oldenburg, J., Paintaud, G., R. Pedersen, C., Ruperto, N., Seitz, R., Spindeldreher, S., Deisenhammer, F.

“…Summary Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to…”
Get full text

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom by Spelman, Timothy, Herring, William L., Zhang, Yuanhui, Tempest, Michael, Pearson, Isobel, Freudensprung, Ulrich, Acosta, Carlos, Dort, Thibaut, Hyde, Robert, Havrdova, Eva, Horakova, Dana, Trojano, Maria, De Luca, Giovanna, Lugaresi, Alessandra, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Alroughani, Raed, Pucci, Eugenio, Granella, Franco, Lechner-Scott, Jeannette, Sola, Patrizia, Ferraro, Diana, Grand’Maison, Francois, Terzi, Murat, Rozsa, Csilla, Boz, Cavit, Hupperts, Raymond, Van Pesch, Vincent, Oreja-Guevara, Celia, van der Walt, Anneke, Jokubaitis, Vilija G., Kalincik, Tomas, Butzkueven, Helmut

“…Background Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies,…”
Get full text

Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study by Saposnik, G., Andhavarapu, S., Fernández, Ó., Kim, H.J., Wiendl, H., Foss, M., Zuo, F., Havrdová, E.K., Celius, E., Caceres, F., Magyari, M., Bermel, R., Costa, A., Terzaghi, M., Kalincik, T., Popescu, V., Amato, M.P., Montalban, X., Oh, J.

“…•Therapeutic inertia (TI) is a common phenomenon affecting over 50% of neurologists who manage patients with multiple sclerosis (pwMS).•Factors associated with…”
Get full text